Merlin Biotech, Inc.
Tuesday, June 04, 2024
Start-Up Stadium Session
Oncology
5B
Merlin has a pre-clinical mRNA-delivered immune activator with strong IP with in-vivo and human epi survival data in both pediatric ($100M PRV) and $2B adult markets.
Company Website:
http://www.merlinbiotech.com
Company HQ City
Doylestown
Company HQ State
PA
Company HQ Country
United States
CEO/Top Company Official
Randall N. Hyer
Speakers
)